LONDON, Dec. 22, 2011 /PRNewswire/ -- Marken announced today that Steve Roese is named Vice President of Marken's Global Quality Assurance organization, which will support Marken's continued investment in their expanding network of pharmaceutical service depots around the world. Marken is now accelerating construction of several new depot facilities in Europe, Asia and the US, which will supplement existing locations in Singapore, Mexico and Argentina.
Steve Roese comes to Marken with more than 30 years experience in quality operations at Wyeth Pharmaceuticals (now Pfizer) which included global operations in the consumer health and nutritional products divisions. He has extensive experience in both clinical and commercial manufacturing, packaging and distribution and has routinely interacted with the world's most important regulatory agencies. Prior to Wyeth, Mr. Roese worked with Perrier / Nestle, Abbott Laboratories and General Foods in various quality and operations roles.
"We are excited to welcome Steve to the company," commented Wes Wheeler, CEO of Marken. "Given our emphasis on clinical storage and distribution of drug products, Steve's responsibilities will be a critically important priority for us. Quality has been, and will remain, a key part of our strategy in the future, and Steve's experience in the pharma industry will enable us to take quality to a whole new level."
About Marken Marken is the leading global clinical supply chain service provider dedicated to the pharmaceutical and life sciences industries, supporting over 6,000 investigator sites in more than 100 countries. With decades of experience in the logistics, transport and distribution of temperature sensitive life saving pharmaceuticals, clinical trial supplies and specimen collection; Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies. Our team members and network of facilities bridge the distance between patients and the essential resources of life science companies.